52 related articles for article (PubMed ID: 1692258)
1. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
2. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.
Levin LV; Griffin TW; Childs LR; Davis S; Haagensen DE
Cancer Immunol Immunother; 1987; 24(3):202-6. PubMed ID: 3496151
[TBL] [Abstract][Full Text] [Related]
3. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
4. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
5. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Brusa P; Dosio F; Pietribiasi F; Delprino L; Feraiorni P; Mariani M; Bussolati G; Cattel L
Cancer Immunol Immunother; 1992; 35(6):373-80. PubMed ID: 1394342
[TBL] [Abstract][Full Text] [Related]
6. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Rostaing-Capaillon O; Casellas P
Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
[TBL] [Abstract][Full Text] [Related]
7. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
Cattel L; Delprino L; Brusa P; Dosio F; Comoglio PM; Prat M
Cancer Immunol Immunother; 1988; 27(3):233-40. PubMed ID: 3263208
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.
Derbyshire EJ; Stahel RA; Wawrzynczak EJ
Cancer Immunol Immunother; 1992; 35(6):417-20. PubMed ID: 1327529
[TBL] [Abstract][Full Text] [Related]
9. An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain.
Eccles SA; McIntosh DP; Purvies HP; Cumber AJ; Parnell GD; Forrester JA; Styles JM; Dean CJ
Cancer Immunol Immunother; 1987; 24(1):37-41. PubMed ID: 3493071
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins.
Vooijs WC; Post J; Wijdenes J; Schuurman HJ; Bolognesi A; Polito L; Stirpe F; Bast EJ; de Gast GC
Cancer Immunol Immunother; 1996 Jul; 42(6):319-28. PubMed ID: 8830734
[TBL] [Abstract][Full Text] [Related]
11. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide.
Kerr DE; Senter PD; Burnett WV; Hirschberg DL; Hellström I; Hellström KE
Cancer Immunol Immunother; 1990; 31(4):202-6. PubMed ID: 2116231
[TBL] [Abstract][Full Text] [Related]
12. Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.
Bjorn MJ; Smith HS; Dairkee SH
Cancer Immunol Immunother; 1988; 26(2):121-4. PubMed ID: 3258792
[TBL] [Abstract][Full Text] [Related]
13. Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects.
Kikuchi T; Ohnuma T; Holland JF; Spitler LE
Cancer Immunol Immunother; 1992; 35(5):302-6. PubMed ID: 1394334
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer.
Goodman GE; Hellstrom I; Yelton DE; Murray JL; O'Hara S; Meaker E; Zeigler L; Palazollo P; Nicaise C; Usakewicz J
Cancer Immunol Immunother; 1993; 36(4):267-73. PubMed ID: 8382560
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
Webb KS; Liberman SN; Ware JL; Walther PJ
Cancer Immunol Immunother; 1986; 21(2):100-6. PubMed ID: 2418949
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.
Lavie E; Hirschberg DL; Schreiber G; Thor K; Hill L; Hellstrom I; Hellstrom KE
Cancer Immunol Immunother; 1991; 33(4):223-30. PubMed ID: 2059966
[TBL] [Abstract][Full Text] [Related]
17. Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin.
Ahmadi Moghaddam Y; Maroufi A; Zareei S; Irani M
Front Mol Biosci; 2023; 10():1098365. PubMed ID: 36936983
[TBL] [Abstract][Full Text] [Related]
18. Exploring the nucleotide molecular mechanism of compound kushen injection for lung adenocarcinoma based on network pharmacology and molecular docking.
Ye Z; Yao X; Chen Z; Jin Q; You Q
Front Oncol; 2022; 12():1013052. PubMed ID: 36419898
[TBL] [Abstract][Full Text] [Related]
19. Directing ricin-based immunotoxins with targeting affibodies and KDEL signal peptide to cancer cells effectively induces apoptosis and tumor suppression.
Park SG; Kim H; Jun H; Choi SY; Kim E; Kang S
J Nanobiotechnology; 2022 Aug; 20(1):387. PubMed ID: 35999603
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxin Therapy for Lung Cancer.
Xie LY; Piao HL; Fan M; Zhang Z; Wang C; Bigner DD; Bao XH
Chin Med J (Engl); 2017 Mar; 130(5):607-612. PubMed ID: 28229994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
